Cargando…

Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5

Two hypomethylating agents (HMAs), azacitidine and decitabine, have demonstrated clinical activities in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML); however, potential problems include development of acquired resistance. HMA-resistant patients have very poor prognosis and this co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hur, Eun-Hye, Jung, Seung-Hyun, Goo, Bon-Kwan, Moon, Juhyun, Choi, Yunsuk, Choi, Dae Ro, Chung, Yeun-Jun, Lee, Je-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355301/ https://www.ncbi.nlm.nih.gov/pubmed/28052028 http://dx.doi.org/10.18632/oncotarget.14342

Ejemplares similares

Changes in Apoptotic Pathways in MOLM-13 Cell Lines after Induction of Resistance to Hypomethylating Agents
por: Janotka, Ľuboš, et al.
Publicado: (2021)

Validation of CRISPR targeting for proliferation and cytarabine resistance control genes in the acute myeloid leukemia cell line MOLM-13
por: Prajapati, Subhash C, et al.
Publicado: (2022)

Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome
por: Choi, Yunsuk, et al.
Publicado: (2019)

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax
por: Fooks, Katie, et al.
Publicado: (2022)

Betulinic Acid–Doxorubicin-Drug Combination Induced Apoptotic Death via ROS Stimulation in a Relapsed AML MOLM-13 Cell Model
por: Vu, Milan, et al.
Publicado: (2021)

Effect of Different Fat and Moringa oleifera Leaf Meal (MOLM) Inclusion Levels on Proximate Composition, Fatty Acid Profile, and Lipid Oxidation of Chicken Droëwors
por: Tembela, Nelisiwe, et al.
Publicado: (2022)

Doxorubicin selectively induces apoptosis through the inhibition of a novel isoform of Bcl-2 in acute myeloid leukaemia MOLM-13 cells with reduced Beclin 1 expression
por: Vu, Milan, et al.
Publicado: (2020)

Inhibition of DNMT3B and PI3K/AKT/mTOR and ERK Pathways as a Novel Mechanism of Volasertib on Hypomethylating Agent-Resistant Cells
por: Choi, Eun-Ji, et al.
Publicado: (2023)

Lack of cross‐resistance to FF‐10501, an inhibitor of inosine‐5′‐monophosphate dehydrogenase, in azacitidine‐resistant cell lines selected from SKM‐1 and MOLM‐13 leukemia cell lines
por: Murase, Motohiko, et al.
Publicado: (2016)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells
por: Hur, Eun-Hye, et al.
Publicado: (2017)

Antileukemic activity of YPN-005, a CDK7 inhibitor, inducing apoptosis through c-MYC and FLT3 suppression in acute myeloid leukemia
por: Koo, Bon-Kwan, et al.
Publicado: (2022)

Effects of Treatment with the Hypomethylating Agent 5-aza-2′-deoxycytidine in Murine Type II Collagen-Induced Arthritis
por: Petralia, Maria Cristina, et al.
Publicado: (2019)

The Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Genome-Wide Hypomethylation in Rice
por: Liu, Shuo, et al.
Publicado: (2022)

4-Phenyl-1,2,4-triazaspiro[4.5]dec-1-ene-3-thione
por: Akkurt, Mehmet, et al.
Publicado: (2013)

The Potential Roles of Dec1 and Dec2 in Periodontal Inflammation
por: Wang, Xingzhi, et al.
Publicado: (2021)

Five-aza-2′-deoxycytidine-induced hypomethylation of cholesterol 25-hydroxylase gene is responsible for cell death of myelodysplasia/leukemia cells
por: Tsujioka, Takayuki, et al.
Publicado: (2015)

Identification of a class of human cancer germline genes with transcriptional silencing refractory to the hypomethylating drug 5-aza-2′-deoxycytidine.
por: Almatrafi, Ahmed, et al.
Publicado: (2014)

A27 DNA HYPOMETHYLATION INDUCED BY 5-AZA-CDR OR LOSS OF DNMT1 INHIBITS COLITIS-ASSOCIATED COLORECTAL CANCER
por: Larsen, F, et al.
Publicado: (2023)

DEC VT220
Publicado: (1983)

Milestone Dec. 85
Publicado: (1985)

Milestone Dec 85
Publicado: (1985)

DEC1 and DEC2 Crosstalk between Circadian Rhythm and Tumor Progression
por: Sato, Fuyuki, et al.
Publicado: (2016)

General Bill of Mortality for London, from Dec. 1835, to Dec. 15, 1836
Publicado: (1837)

Redetermination of the structure of 2-amino-8-thia-1,5-diazaspiro[4.5]dec-1-en-5-ium chloride monohydrate
por: Kayukova, Lyudmila A., et al.
Publicado: (2022)

Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents
por: Kang, Ka-Won, et al.
Publicado: (2020)

THU498 Establishing The Link Between Glucocorticoid Signaling And The Circadian Regulator DEC1 In Breast Cancer
por: Castro, Mikaela I, et al.
Publicado: (2023)

Stra13/DEC1 and DEC2 inhibit sterol regulatory element binding protein-1c in a hypoxia-inducible factor-dependent mechanism
por: Choi, Su Mi, et al.
Publicado: (2008)

NY DEC Takes on Fracking
por: Schmidt, Charles W.
Publicado: (2011)

Milestone Dec. 85/5
Publicado: (1985)

Milestone Dec. 85/7
Publicado: (1985)

Milestone Dec. 85/6
por: de Metz-Noblat, N
Publicado: (1985)

Meeting of Dec. 19, 1881
Publicado: (1882)

Meeting of Dec. 21, 1874
Publicado: (1875)

Hyperlipidemia May Synergize with Hypomethylation in Establishing Trained Immunity and Promoting Inflammation in NASH and NAFLD
por: Drummer, Charles I. V., et al.
Publicado: (2021)

2-(3,5-Dioxo-4-azatricyclo[5.2.1.0(2,6)]dec-8-en-4-yl)acetic acid
por: Akkurt, Mehmet, et al.
Publicado: (2013)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

4-(2-Aminophenyl)-10-oxa-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione
por: Li, Jian
Publicado: (2011)

Induced Morphological Changes in Larval Rock Bream, Oplegnathus fasciatus, under Starvation
por: Park, In-Seok, et al.
Publicado: (2013)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e76o9qv2pko2i985ujhmcer6s9